We have secured five United States patents and have pending applications for five United States patents and seven foreign patents.  Two of the United States issued patents have been assigned for a fee to Celgene Corporation for the pulsed released delivery of methylphenidate.

The pending patent applications relate to four different control release pharmaceutical products on which we are working.  Included among these patent applications are applications for the U.S. patents relating to formulations for delayed and sustained release of drugs.  In addition, an application for a U.S. patent for a narcotic antagonist product that we are developing to be used with Oxycodone and other narcotics to minimize the abuse potential for the narcotics was filed.